News Article
Acquisitions and product enhancements expand disease and nanotechnology research capabilities
Agilent acquisition and portfolio enhancement announcements in support of disease and nanotechnology research.
In the acquisition space, Agilent announced it has signed an agreement to acquire TILL Photonics GmbH and has completed the acquisition of Colloidal Dynamics. TILL Photonics develops and markets innovative life science products for fluorescence microscopy. Such products help researchers investigate diseases, such as Alzheimer's, on a cellular level, providing a deeper understanding of how live cells behave in their natural environment to help develop improved treatments. The acquisition will complement Agilent's atomic force microscope (AFM) platform and is consistent with Agilent's strategy of providing customers with comprehensive workflow solutions. The acquisition of privately held Colloidal Dynamics provides Agilent the unique opportunity to accelerate its entry into the particle characterisation market and enables the company to offer a complete portfolio of the most effective and accurate particle-measurement solutions, a one stop shop. This acquisition addresses the needs of customers that require a variety of measurement capabilities at the nanoscale and at high concentration with applications in the polymer, specialty chemical, inks/pigments, food, pharmaceutical, and materials research markets.